Analysis of gut microbiota in patients with neuromuscular syndromes compared to control-groups

Analysis of gut microbiota in patients with neuromuscular syndromes compared to control-groups - MYBIOM

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00017134

Enrollment

100

Registered

2020-04-03

Start date

2017-07-15

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G70.0 G70.8

Interventions

Group 1: Analysis of gut microbiota in one stool sample of 40 patients with myasthenia gravis Group 2: Analysis of gut microbiota in one stool sample of 20 control patients (i.e. stroke, headache, Par

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosed myasthenia gravis or disorders of the control group; legal age; signed consent

Exclusion criteria

Exclusion criteria: chronic-inflammatory bowel diseases (i.e. colitis ulcerosa); short bowel syndrome; irritable bowel syndrome; intake of probiotics within the last 3 months; history of bowel resection; intake of antibiotics within the last month; pregnancy

Design outcomes

Primary

Measure	Time frame
Significant alteration of gut microbiota of patients with myasthenia gravis compared to control patients (with non-inflammatory neurological diseases or with other autoimmune diseases of the peripheral nervous system).	—

Secondary

Measure	Time frame
Significant alteration of gut microbiota of patients with myasthenia gravis compared to healthy controls	—

Countries

Germany

Contacts

Public ContactAndreas Totzeck

Klinik für Neurologie, Universitätsmedizin Essen

andreas.totzeck@uk-essen.de0201 – 723 - 6302

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026